the PA-CL-CHINA-01 study

VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China

Retrieved on: 
Friday, April 30, 2021

The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.\nDr.

Key Points: 
  • The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.\nDr.
  • In 2020, Velphoro\xc2\xae became a global leader by value in the calcium-free phosphate binder market2.\n1 Zhang et al.
  • Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005950/en/\n'